KR101098241B1 - Lactobacillus sp. HY7801 having inhibitory effect against urinary tract infection and candidiasis, and products containing thereof as effective component - Google Patents

Abstract

The present invention is Lactobacillus sp. HY7801 and a pharmaceutical composition, fermented milk, beverage and health functional food containing the same as an active ingredient, Lactobacillus sp. HY7801 is Urinary Tract of Escherichia coli (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus (Staphylococcus aureus), Acinetobacter half Mani (Acinetobacter banmanii) inhibition, exhibits activity for inhibiting pathogen adhesion to urinary bladder epithelial cells of E. coli, in which the infection of E. coli urinary tract infections It shows the activity of inhibiting bladder inflammation in the experimental animal model, and the activity of inhibiting Candida albicans , which causes candida vaginitis, has excellent ability to produce hydrogen peroxide, an antimicrobial substance, and has excellent adhesion to vaginal epithelial cells. Therefore, it can be used as a formal preparation, fermented food or health functional food for the purpose of treatment and / or prevention of urinary tract infection and candida vaginitis.

Hydrogen peroxide, lactobacillus, urinary tract infection, vaginitis, Candida albicans, E. coli

Description

Lactobacillus espi with activity that inhibits urinary tract infections and candida vaginitis. H. Y 7801 and a product containing the same as an active ingredient {Lactobacillus sp. HY7801 having inhibitory effect against urinary tract infection and candidiasis, and products containing according as effective component}

The present invention is a novel Lactobacillus sp. With activity inhibiting urinary tract infection and candida vaginitis. HY7801 and as it relates to a product containing as an active ingredient, and more particularly, E. coli (E. coli), Proteus vulgaris (Proteus vulgaris) Urinary Tract, Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa ), Streptococcus aureus ( Staphylococcus) aureus), Acinetobacter half Mani (Acinetobacter banmanii) inhibition and, Urinary Tract Escherichia coli (E. coli) of naemyeo or other active that suppresses attachment to the bladder epithelial cells, causing Candida vaginitis St. Candida albicans (Candida albicans ) Inhibits urinary tract infections and candida vaginitis due to its ability to produce hydrogen peroxide, an antibacterial substance, and excellent adhesion to vaginal epithelial cells. HY7801 and a product containing the same as an active ingredient.

Urinary tract infection (UTI) occurs at any time during life in women and occurs frequently in childhood and old age in men. Urinary tract infections include cystitis, pyelonephritis, asymptomatic bacteriuria, and complications associated with kidney stones and catheterization. Infections and recurrent urinary tract infections. In particular, as one of the most common bacterial infectious diseases in pediatric age, infants under 1 years of age is common enough to account for about 5% of the causes of fever. Repetitive diagnosis of the cause of urinary tract infections can lead to advanced renal disease that can lead to permanent kidney failure, so early diagnosis and treatment of urinary tract infections is very important. The causative agents of urinary tract infections in children include E. coli , Proteus spp., Klesiella spp., Enterococcus spp., Enterobacter spp., Pseudomonas spp., Staphylococcus aureus , Group B streptococcus and Salmonella , among which E. coli It accounts for more than 80% and is known as the most important causative organism. E. coli can be divided into three groups according to clinical and genetic information. Intestinal resident bacteria are commensal strains that can only be pathogenic only in environmental changes such as immune defects and tube insertions of the host, and intestinal strains that catalyze enteritis. It causes a variety of infections of all ages and all organs and is classified as an extarintestinal strain, especially the main pathogenicity of urinary tract infections.

Overseas, the resistance of antibiotics to the urinary tract infection caused by Escherichia coli has recently emerged seriously. In the past, Escherichia coli was susceptible to aminopenicillin-based beta-lactam antibiotics, and antibiotics such as ampicillin and amoxicillin, which are oral beta-lactam-based aminopenicillin antibiotics, were the first choice drugs. It has been reported that the resistance to antibiotics is significantly increased, and the multidrug resistance, which is also resistant to some cephalosporins, quinolone antibiotics, and sulfa antibiotics, has become a serious problem. And Escherichia coli causing urinary tract infections Recently, it is pointed out that an increase in the generation of extended spectrum beta-lactamase (ESBL) producing bacteria that hydrolyzes antibiotics such as penicillin, third-generation cephalosporin, and monobactam is also pointed out.

Vaginitis is a disease caused by a fungal infection that occurs more than once in about three quarters of the female population. It is divided into three major causes: bacterial vaginosis (BV), candida vaginitis (CV), and trichomonas. Vaginitis (Trichomonas vaginalis). Among these, bacterial vaginitis has recently been recognized as the most common vaginitis, and vaginal secretions isolated from patients with bacterial vaginitis are Atopobium vaginae , Megasphaera sp., Gardnerella vaginalis , Eggerthella sp., Clostridium -like sp., Prevotella bivia group, Peptostreptococcus micros , Prevotella sp. It has been reported to have been found, especially Gardnerella vaginalis is known as the main causative agent.

Recently, the possibility of preventing urinary tract infection using probiotic lactobacilli ( Lactobacilli ) has been reported. Especially, in animal experiments, Lactobacillus casei shirota shows antibacterial activity against Escherichia coli, the causative agent of urinary tract infection, It has been reported that it may be used as a treatment for urinary tract infections.

On the other hand, lactobacillus predominantly in the vagina of women is known to reduce the risk of bacterial vaginosis and urinary tract infection. In general, the vagina of healthy women is known as the most important defense means to suppress the growth of other pathogenic microorganisms by maintaining the vaginal pH of less than 4.5 as the various types of lactobacillus group. In particular, the bacterial vaginitis Staphylococcus sp., Clostridium sp., Prevotella sp., Gardnerella vaginalis, Atopobium vaginae like this was the normal one, while the like distributed mainly Lactobacillus iners, Lactobacillus acidophilus mainly distribution in the patient candidiasis distribution of L. acidophilus Has been reported to be very low. The mechanism of the probiotic lactobacillus inhibitory effect on vaginitis or urinary tract infection is due to competition for adhesion receptors against the causative organism, competition for nutrients, and hydrogen peroxide (H ₂ O ₂ ) lactic acid, bacteriocin, and other antibacterial agents. Reported to be due to a substance. Since the treatment of vaginitis by antibiotics has a high possibility of recurrence, many attempts have been made to concurrently treat vaginitis by inducing dominant vaginal lactobacillus. Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14 have been studied as representative lactic acid strains for the prevention and treatment of urinary tract infection and vaginitis. Currently, L. rhamnosus GG (Valio), L. acidophilus NCFM (Rhodia), L. casei DN-114 (Actimel), L. acidophilus SIDU (SIDU Enterprises), L. johnsonii LJ1 (Nestle), and L. plantarum 299V (Probi) are known as urogenital probiotic lactobacilli ( Lactobacilli ). Edo is being researched to isolate probiotics by separating various lactic acid bacteria from the vagina of women.

On the other hand, lactic acid bacteria are widely distributed in human oral cavity, intestine, vagina, feces and the like. Therefore, a method of obtaining lactic acid bacteria having desired properties by separating the lactic acid bacteria and testing the properties thereof has been performed, and in particular, a method of separating the lactic acid bacteria from feces has been usefully used. Accordingly, the present inventors, in consideration of maximizing the useful effect of lactic acid bacteria in the relationship of host specificity, in order to isolate a strain suitable for preparing fermentation products suitable for Korean physiology, the lactic acid bacteria were tested from the feces of Korean adults and newborns, and the mutation was induced. Antimutagenicity against the original 4-NQO, inhibition of enteric harmful bacteria Clostridium perfringens and Bacteroides vulgatus associated with colitis induction, chondroitinase associated with inflammation of the colon mucosa By inhibiting TLR4 associated with inhibition and proinflammatory cytokine secretion, Lactobacillus sp. HY7801 was discovered and the Republic of Korea Patent Application No. 10-2008-0057422 (name of the invention: Lactobacillus sp. HY7801 having a health promoting effect of the large intestine and products containing it as an active ingredient), in addition to the present inventors The present invention was completed by newly discovering the activity of inhibiting urinary tract infection bacteria and Candida albicans.

The present invention is E. coli Urinary Tract (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Inhibits Streptococcus aureus and Acinetobacter banmanii , inhibits adhesion to bladder epithelial cells of the U. urea bacterium E. coli , and has excellent antibacterial hydrogen peroxide production ability. Lactobacillus sp. Characterized by having an inhibitory activity. An object of the present invention is to provide HY7801 and a pharmaceutical composition, fermented milk, a beverage and a dietary supplement containing the same as an active ingredient.

In addition, the present invention exhibits the activity of inhibiting Candida albicans that causes candida vaginitis, has excellent adhesion to vaginal epithelial cells, and excellent ability to produce hydrogen peroxide, an antibacterial substance, to inhibit Candida vaginitis. Lactobacillus sp. An object of the present invention is to provide HY7801 and a pharmaceutical composition, fermented milk, a beverage and a dietary supplement containing the same as an active ingredient.

In order to achieve the above object, the present invention is E. coli Urinary Tract (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Inhibits Streptococcus aureus and Acinetobacter banmanii , inhibits adhesion to bladder epithelial cells of the U. urea bacterium E. coli , and has excellent antibacterial hydrogen peroxide production ability. Lactobacillus sp. Having inhibitory activity. And HY7801 and a pharmaceutical composition containing the same as an active ingredient, fermented milk, a beverage and a dietary supplement.

In addition, the present invention exhibits the activity of inhibiting Candida albicans that causes candida vaginitis, has excellent adhesion to vaginal epithelial cells, and excellent ability to produce hydrogen peroxide, an antibacterial substance, to inhibit Candida vaginitis. Having Lactobacillus sp. And HY7801 and a pharmaceutical composition containing the same as an active ingredient, fermented milk, a beverage and a dietary supplement.

Hereinafter, the present invention will be described in detail.

In order to isolate the strain according to the present invention, feces of healthy Korean adults and newborns were placed in MRS liquid medium containing 0.02% sodium azide and incubated at 37 ° C for 24 hours. After incubation, 10 μl platinum was used to collect the culture medium, which was then plated on an MS agar plate containing 0.02% sodium azide and incubated at 37 ° C. for 2 days. Antimutagenicity of mutagen 4-NQO among these fungi, inhibition of intestinal harmful bacteria Clostridium perfringens and colitis-induced Bacteroides vulgatus and inflammation of the colonic mucosa Strains of the invention were isolated by testing for intestinal mutagen suppression, harmful bacterium suppression and pro-inflammatory activity by inhibiting chondroitinase inhibition associated with and TLR4 associated with proinflammatory cytokine secretion.

The characteristics of the lactic acid bacteria according to the present invention are as follows.

1) Form of bacteria

   Characteristics of Bacteria When incubated in MRS Agar Plate Medium at 37 ° C for 2 Days

    ① Cell Type: Bacillus

    ② Mobility: None

    ③ Sporulation ability: None

    ④Gram staining: positive

2) Form of the collapse

  Form of fungi when incubated for 2 days at 37 ° C on MRS agar plate medium

    ① Shape: Round

    ② bump: convex

    ③ Surface: Smooth

3) physiological properties

    ① Optimal growth temperature: 36 ~ 38 ℃

    ②Optimum growth pH: 6.0 ~ 6.5

    ③ Effects on oxygen: anaerobic anaerobic

Catalase:-

5) Whether gas is formed:-

6) Growth at 15 ℃:-

7) Growth at 45 ℃: +

8) Indole Production:-

9) lactic acid production: +

10) sugar usability test

Sugar availability test was performed using Api 50CHL kit (BIOMERIEUX).

The results are shown in Tables 1 and 2 below.

11) 16S rDNA Analysis

Molecular genetic methods through 16S rDNA analysis were performed to identify new strains of the present invention.

The 16S rDNA sequencing results are shown in Table 3 (<http://www.ncbi.nlm.nih.gov/blast>).

As can be seen in Table 3, 16S rRNA gene of the new strain of the present invention is Lactobacillus acidophilus , Lactobacillus suntoryeus and Lactobacillus helveticus ( Lactobacillus helveticus ) 16S 100% match with the rRNA gene.

As a result of the above identified morphological characteristics, physiological and growth characteristics of the new strain of the present invention, the sugar availability of the Api 50CHL kit (BIOMERIEUX) and molecular genetic method through 16S rDNA analysis, the new strain of the present invention It was found to belong to the genus Lactobacillus, but did not identify the species (species).

Therefore, the inventors of the present invention the Lactobacillus sp. It was named HY7801 and was deposited on April 17, 2008 at Korea Institute of Bioscience and Biotechnology (Accession No .: KCTC 11315BP).

On the other hand, Lactobacillus sp. Has the activity of inhibiting urinary tract infection and candida vaginitis of the present invention. Pharmaceutical compositions for the treatment and prophylaxis of urinary tract infection and candida vaginitis containing HY7801 as an active ingredient may be prepared in the form of preparations such as tablets, capsules, etc. according to the methods commonly used pharmaceutically or in combination with excipients used alone or pharmaceutically. Can be formulated and used.

For humans, a typical daily dose may range from 1-30 mg / kg body weight and may be administered once or in divided doses. However, the actual dosage should be determined in light of several relevant factors such as the route of administration, the age, sex and weight of the patient, health condition and severity of the disease. Of course, Lactobacillus sp. Has the activity of inhibiting urinary tract infection and candida vaginitis of the present invention. The pharmaceutical composition for the treatment and prevention of urinary tract infection and candida vaginitis containing HY7801 as an active ingredient has little toxicity and side effects, and therefore, it is a drug that can be used safely for long-term use for prophylactic purposes.

In addition, Lactobacillus sp. Fermented milk for the prevention of urinary tract infection and candida vaginitis containing HY7801 as an active ingredient is lactobacillus culture liquid, Lactobacillus sp. HY7801 and mixed juice syrup is combined at a constant rate, homogenized at 150 bar, cooled to 10 ° C. or less, and then packaged in a container to prepare fermented milk.

In addition, Lactobacillus sp. Beverages for the prevention of urinary tract infection and candida vaginitis containing HY7801 as an active ingredient are mixed fruit syrup, Lactobacillus sp. HY7801 and water in a uniform ratio, homogenized at 150 bar, cooled to 10 ℃ or less and then packaged in small packaging containers such as glass bottles, plastic bottles to produce a functional beverage.

In addition, Lactobacillus sp. Functional foods for the prevention of urinary tract infection and candida vaginitis containing HY7801 as an active ingredient is the Lactobacillus sp. In addition to HY7801, vitamin B1, B2, B5, B6, E and acetate esters, nicotinic acid amide, oligosaccharides, etc. may be added as nutritional supplements, and other food additives may be added.

As described above, the Lactobacillus sp. Of the present invention. HY7801 is E. coli, proteus vulgaris, Proteus Mirabilis, Klebsiella oxytoca, Krebselaa Pneumoniae, Morgana Morgana, Sightseeing Baptistery, Enkerokocus Picalis, Enterobacter Chloka, Pseudomonas Aruginosa, Streptococcus aureus, ahsine tobak emitter to half manieul suppressed, exhibits Urinary Tract E. coli the activity of suppressing the attachment to the bladder epithelial cells, inhibit bladder inflammation of the urinary tract infections in experimental animals models infected with E. coli It is an antifungal agent for the purpose of treating and preventing urinary tract infections and candida vaginitis by showing activity, inhibiting Candida albicans which causes candida vaginitis, and having excellent ability to produce hydrogen peroxide, an antimicrobial substance, and adhere to vaginal epithelial cells. It can be used as fermented food or health functional food.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are not intended to limit the scope of the present invention, and ordinary changes by those skilled in the art are possible within the scope of the technical idea of the present invention.

&Lt; Example 1 >

Lactobacillus sp. Lyophilized powder production including HY7801

Lactobacillus sp of the present invention. HY7801 is a liquid medium containing Proteose peptone # 3 for food raw materials, Yeast Extract, Beef Extract, and glucose, incubated at 37 ° C for about 20 hours, centrifuged and washed with sterile saline, and then in sterile milk. Dispersed. Freeze-drying again yielded about 10 ¹¹ cfu bacteria per gram (g) of lyophilized powder. The lyophilized powder was treated with Lactobacillus sp. Urinary tract infection and Candida vaginitis containing HY7801 as an active ingredient was used as a material for the treatment and prevention.

Meanwhile, Lactobacillus sp. HY7801 may be provided in the form of a lyophilized powder or culture as described above.

<Example 2>

Lactobacillus sp. Preparation of a pharmaceutical composition containing HY7801 as an active ingredient

Lactobacillus sp. Has an activity of inhibiting urinary tract infection and candida vaginitis of the present invention. Examples of the pharmaceutical composition containing HY7801 as an active ingredient will be described, but the present invention is not intended to be limited thereto, but is intended to be described in detail.

Manufacture of tablets

Lactobacillus sp. 100 mg of lyophilized powder including HY7801, 100 mg of corn starch, 100 mg of lactose, and 97 mg of polyvinylpyrrolidone were homogeneously mixed, granulated by wet granulation, 2 mg of magnesium stearate was added, and then 400 mg of one tablet. It was compressed to be.

Preparation of Capsules

Lactobacillus sp. A lyophilized powder including HY7801, 100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate were thoroughly mixed and then filled into hard gelatin capsules according to a conventional method for preparing a capsule to prepare a capsule.

<Example 3>

Lactobacillus sp. Preparation of fermented milk containing HY7801 as an active ingredient

Lactobacillus culture medium and Lactobacillus sp having an activity of inhibiting urinary tract infection and candida vaginitis of the present invention. Method for producing a fermented milk consisting of HY7801 and mixed juice syrup is as follows.

First, the lactic acid bacteria culture medium was stirred at 95.36% by weight of crude milk and 4.6% by weight of skim milk powder (or mixed milk powder), and the specific gravity at 15 ° C was 1.0473 to 1.0475, the titratable acidity was 0.200 to 0.220%, and the pH was 6.65 to 6.70, 20 ° C. Brix ^o was mixed to be 16.3 ~ 16.5%. After mixing, it was UHT heat-treated (sterilized at 135 ° C for 2 seconds), cooled to 40 ° C, and then Streptococcus thermophilus and Lactobacillus (Valley laboratory, USA) were added at 0.02% by weight, respectively, and incubated for 6 hours, followed by BCP. Total lactic acid bacteria in the medium was 1.0 × 10 ⁹ cfu / ㎖ or more, the titratable acidity was 0.89 ~ 0.91%, pH was prepared to be 4.55 ~ 4.65.

Next, the mixed fruit syrup is 13% by weight liquid fructose, 5% by weight white sugar, 10.9% by weight mixed juice concentrate 56Brix ^o , 1.0% by weight pectin, 0.1% by weight fresh fruit mix essence and 70% by weight purified water at 30 ~ 35 ℃ After mixing by stirring, UHT heat treatment (sterilized for 2 seconds at 135 ℃) and then prepared by cooling.

Then, 69.5% by weight of the lactic acid bacteria culture solution and Lactobacillus sp. 0.1% by weight of lyophilized powder containing HY7801 and 30.4% by weight of the blended juice syrup was homogenized at 150 bar and then cooled to 10 ° C. or lower to inhibit urinary tract infection and candida vaginitis. Fermented milk containing HY7801 as an active ingredient was prepared.

<Example 4>

Lactobacillus sp. Preparation of functional drink containing HY7801 as an active ingredient

Lactobacillus sp. Has an activity of inhibiting urinary tract infection and candida vaginitis of the present invention. Method for producing a functional beverage consisting of HY7801 and mixed juice syrup is as follows.

First, mixed fruit syrup is 13% by weight of liquid fructose, 2.5% by weight of white sugar, 2.5% by weight of brown sugar, 56% by weight of mixed juice concentrate 56Brix ^o , 1.0% by weight pectin, 0.1% by weight of fresh fruit mix essence and 70% by weight of purified water After mixing by stirring at 30 ~ 35 ℃ UHT heat treatment (sterilized for 2 seconds at 135 ℃) was prepared by cooling.

And 30.4% by weight of the mixed fruit juice syrup prepared by the above method and the Lactobacillus sp. 0.1% by weight of lyophilized powder containing HY7801 and 69.5% by weight of the remaining purified water were homogenized at 150 bar, cooled to 10 ° C or lower, and then packaged in small packaging containers such as glass bottles and plastic bottles to inhibit urinary tract infection and candidiasis vaginitis. Lactobacillus sp. A functional beverage containing HY7801 as an active ingredient was prepared.

Example 5

Lactobacillus sp. Preparation of health functional food containing HY7801 as an active ingredient

Lactobacillus sp. To 0.1% by weight of the lyophilized powder containing HY7801, nutritional supplements (vitamins B1, B2, B5, B6, E and acetate esters, nicotinic acid amides) and oligosaccharides were added to the Lactobacillus sp. 10 parts by weight based on 100 parts by weight of the lyophilized powder including HY7801 was added and mixed in a high speed rotary mixer. 10 parts by weight of sterile purified water was added to the mixture, mixed, and molded into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum dryer at 40 to 50 ° C., and then uniformly prepared granules were passed through 12 to 14 mesh. The granules prepared as described above were extruded by appropriate amounts into tablets or powders or filled into hard capsules to produce hard capsule products.

<Test Example 1>

Lactobacillus sp. Urinary Tract Infection of HY7801 E. coli  ATCC25922 inhibitory activity measurement

(1) Lactobacillus sp. HY7801 was incubated at 37 ° C. for 20 hours using MS liquid medium (Difco, USA), and E. coli ATCC25922, a major causative agent of urinary tract infection, was inoculated with Tryptic Soy liquid medium (Difco, USA) 37 Shake culture was carried out for 20 hours at ℃ used for the test.

(2) Lactobacillus sp. The method for measuring the inhibitory activity of E. coli ATCC25922 of HY7801 is as follows.

The sterilized metal borer (diameter 6 mm) was arranged in a sterile Petri dish at the position where the well was made, and 28 ml of MS agar medium (Difco, USA) was hardened to make a well. After the medium was completely hardened, E. coli incubated for 20 hours in (1) was inoculated into 5 μl / ml of Tryptic Soy soft agar medium, and then 5 ml of each layer was hardened by agar plate agar plate. Remove the metal borer and put 50 µl each of the MS agar medium in each well to block the bottom of the (1) Lactobacillus sp. 100 μl of HY7801 culture was mixed with 100 μl of sterile distilled water and then inoculated into each well. The size of the inhibitory ring produced by incubating at 37 ^° C. for 24 hours was measured.

Lactobacillus sp. The inhibitory activity of E. coli ATCC25922 by HY7801 was expressed as the length (mm) minus the diameter of the metal borer from the diameter of the produced inhibitory ring.

(3) Lactobacillus plantarum BS-1, Lactobacillus plantarum YS-I9, Lactobacillus sp. L260, Lactobacillus sp. L266, Lactobacillus sp. S3-6, Lactobacillus casei LCW, Lactobacillus sp. 7-3wy1, Lactobacillus casei J2-1, Lactobacillus sp. RM1-5, Lactobacillus sp. RM5-10, Lactobacillus sp. RM6-5R, Lactobacillus sp. RM7-3, Lactobacillus Basil Russ (Lactobacillus) sp. RM8-21w, Lactobacillus rhamnosus GR-1, Lactobacillus sp. CH1-1, Lactobacillus sp. CH7-1, Lactobacillus sp. CH9-2, Lactobacillus sp. CH10-1, Lactobacillus casei HY7211, Lactobacillus sp. CH16-2W2, and Lactobacillus sp. Also for KM5-5, Lactobacillus sp. By the same method as measuring method of inhibiting activity of E. coli ATCC25922 HY7801 it was tested for inhibition of E. coli ATCC25922.

The results are shown in FIG.

1, the longitudinal side is Lactobacillus plantarum BS-1, Lactobacillus plantarum Lactobacillus plantarum YS-I9, Lactobacillus ( Lactobacillus ) sp. L260, Lactobacillus sp. L266, Lactobacillus sp. S3-6, Lactobacillus sp. HY7801, Lactobacillus casei LCW, Lactobacillus sp. 7-3wy1, Lactobacillus casei J2-1, Lactobacillus sp. RM1-5, Lactobacillus sp. RM5-10, Lactobacillus sp. RM6-5R, Lactobacillus sp. RM7-3, Lactobacillus sp. RM8-21w, Lactobacillus rhamnosus GR-1, Lactobacillus sp. CH1-1, Lactobacillus sp. CH7-1, Lactobacillus Basil Russ (Lactobacillus) sp. CH9-2, Lactobacillus sp. CH10-1, Lactobacillus casei HY7211, Lactobacillus sp. CH16-2W2, Lactobacillus sp. KM5-5 is 'BS-1', 'YS-I9', 'L260', 'L266', 'S3-6', 'HY7801', 'LCW', '7-3wy1' and 'J2-1' , 'RM1-5', 'RM5-10', 'RM6-5R', 'RM7-3', 'RM8-21w', 'GR-1', 'CH1-1', 'CH7-1', ' CH9-2 ',' CH10-1 ',' HY7211 ',' CH16-2W2 'and' KM5-5 '.

As can be seen in Figure 1, the Lactobacillus sp of the present invention. The largest inhibitory ring of E. coli ATCC25922 of HY7801 was 6.7 mm, indicating the highest inhibitory activity against urinary tract infection E. coli ATCC25922.

<Test Example 2>

Lactobacillus sp. Determination of Inhibitory Activity of Other Urinary Tract Infections of HY7801

(1) Lactobacillus sp. HY7801 is emal S was using the broth using a 20 hour incubation test In 37 ℃, the Urinary Tract of Proteus vulgaris isolated in Korea urinary tract infections (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streplococcus aureus and Acinetobacter banmanii were inoculated in Tryptic Soy liquid medium and shaken at 37 ° C. for 20 hours to be used for the test.

(2) Lactobacillus sp. Other methods of inhibiting urinary tract infections of HY7801 are as follows.

The sterilized metal borer (diameter 6 mm) was arranged in a sterile Petri dish at the position where the wells were made, and then 28 ml of MS agar medium was hardened to make wells. After the culture medium completely solidifies the Urinary Tract of Proteus vulgaris in the 20 hours separating the cultured domestic urinary tract infection of the (1) (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus ( Staphylococcus aureus ) and Acinetobacter banmanii were inoculated in 5 μl / ml in Tryptic Soy soft agar medium, and then layered and hardened in 5 ml each of agar agar plate medium. Remove the metal borer and put 50 µl each of the MS agar medium in each well to block the bottom of the (1) Lactobacillus sp. 100 μl of HY7801 culture was mixed with 100 μl of sterile distilled water, and then inoculated into each well. The size of the inhibitory ring produced by incubating at 37 ^° C. for 24 hours was measured.

Lactobacillus sp. The Urinary Tract Proteus vulgaris is separate from domestic urinary tract infections caused by HY7801 (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Inhibitory activity of Streplococcus aureus and Acinetobacter banmanii was expressed as the length of the metal borer minus the diameter of the resulting inhibitor ring.

(3) Lactobacillus plantarum BS-1, Lactobacillus casei ( Lactobacillus casei ) LCW, which are strains having an inhibitory ring size of 6.0 mm or more in the measurement result of inhibition activity of E. coli ATCC25922 in Test Example 1; Lactobacillus casei J2-1, Lactobacillus sp. RM1-5, Lactobacillus rhamnosus GR-1, Lactobacillus sp. CH7-1, and Lactobacillus casei HY7211, Lactobacillus sp. Proteus vulgaris (Proteus vulgaris) in the same manner as the Urinary Tract HY7801, Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Inhibitory activity of Streplococcus aureus and Acinetobacter banmanii was tested.

The results are shown in Table 4 below.

As can be seen in Table 4, the Lactobacillus sp. Proteus vulgaris (Proteus vulgaris) of HY7801 Other Urinary Tract, Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus ( Staphylococcus aureus ), Acinetobacter banmanii ( Acinetobacter banmanii ) has the highest inhibitory activity against the urinary tract infection bacterium was confirmed that it was excellent.

<Test Example 3>

Lactobacillus sp. By HY7801 E. coli Determination of Adhesion Inhibition Activity in Human Bladder Epithelial Like Cells

Lactobacillus sp. Inhibition of E. coli adhesion to human bladder epithelial like cells of HY7801 was tested.

(1) T24 cells were used for the human bladder carcinoma cells used in the test. First, T24 cells were put in 6 ml plates (or 24 well plates), 2 ml, 10% FBS was added, and RPMI1640 medium without antibiotics (Gifco, USA) was added and cultured until it was filled with a monolayer.

(2) Lactobacillus sp. HY7801 was incubated at 37 ° C. for 20 hours using MS liquid medium, and E. coli ATCC25922 was inoculated in Tryptic Soy liquid medium and shaken at 37 ° C. for 20 hours. E. coli ATCC25922 and Lactobacillus sp. HY7801 was centrifuged at 400 rpm for 10 minutes and E. coli and Lactobacillus sp. The HY7801 cells were washed with fresh RPMI1640 medium, and then 100 µl of each T24 cell was incubated. Each well was incubated in a CO ₂ incubator at 37 ° C. for 1 hour and incubated three times with T24 cells with fresh RPMI1640 medium. E. coli and Lactobacillus sp. HY7801 was removed. 150 μl of 10X trypsin-EDTA was added to each well and allowed to stand for 5 minutes. Then, 2 ml of RPMI1640 medium was added to harvest the attached T24 cells, diluted with a dilution solution, and then lactobacillus sp using the following selective medium. . The viable cell counts of HY7801 and E. coli ATCC25922 were measured. Lactobacillus sp. HY7801 was measured using Rogosa SL medium (Difco, USA) and E. coli was measured using EMB medium (Difco, USA), and the number of harvested T24 cells was measured using a hemocytometer. Lactobacillus sp. HY7801 and E. coli were converted into Lactobacillus sp. It is expressed as a percentage inhibition of adhesion of E. coli by HY7801.

Adsorption inhibition of E. coli (%) = (100 - adsorption rate of E. coli)

Adsorption rate (%) of E. coli = 100 X (A / B)

A: Log ₁₀ [ E. coli number / T24 cell number (Lactobacillus sp. HY7801 treatment)]

B: Log ₁₀ [ E. coli number / T24 cell number (Lactobacillus sp. HY7801 untreated)]

(3) Lactobacillus sp. Strains having excellent inhibitory activity in the results of measuring the inhibitory activity of the other urinary tract infections of Test Example 2; RM1-5, Lactobacillus rhamnosus GR-1, Lactobacillus sp. CH7-1 and Lactobacillus casei HY7211 are also Lactobacillus sp. Inhibition of adhesion to T24 cells of E. coli was measured in the same manner as HY7801. The results are shown in Table 5.

As can be seen in Table 5, when attached to the U. coli E. coli and lactic acid bacteria to T24 cells, Lactobacillus sp. It was found that HY7801 significantly inhibited the adhesion of E. coli .

<Test Example 4>

Lactobacillus sp. Inhibition of bladder inflammation of HY7801

Lactobacillus sp. The efficacy of inhibiting bladder inflammation of HY7801 was tested.

(1) Lactobacillus sp. HY7801 is used for testing by culturing S. emal liquid was using a medium with 20 hours incubation at 37 ℃ used for testing, the main cause of urinary tract infection of E. coli ATCC25922 was 20 hours with shaking at 37 ℃ inoculated in Tryptic Soy Broth It was. Each strain was centrifuged at 4,000 rpm for 10 minutes, washed twice with PBS, and used for testing.

(2) SD rats used for the test were purchased from the central laboratory animals and used for the test after the period of purification. The test group was treated with physiological saline only for 1 week from the start of the test, E. coli group infected with physiological saline and later E. coli , and Lactobacillus sp. The test was conducted by dividing HY7801 into HY7801 group that was fed E. coli .

First, the HY7801 group is the Lactobacillus sp. After dispersing HY7801 in physiological saline to 1.0 x 10 ⁹ cfu / ml, 1 ml per rat was administered orally for 1 week. One week after the test, rats were intraperitoneally administered with 100 μl of ketamine per 100 g, followed by E. coli bacteria. 2.4 ml of E. coli bacteria dispersed in physiological saline to 1.0 x 10 ⁷ cfu / ㎖ was divided into three times for E. coli infection by pushing into the urethra of rats at regular intervals and pressure. Bladder was excised at 3 days after E. coli infection, and the excised bladder was soaked in 10% formaldehyde solution for pathological analysis. The colon tissue was embedded with paraffin through the dehydration process of alcohol and the usual method, and hematoxylin-eosin (HE) staining was made by preparing 5 μm-thick serial sections using a thin sectioning machine. Permanent specimens were filled with permount and histopathological analysis was performed.

Likewise, the E. coli family was lactobacillus sp. Except for oral administration of physiological saline only for one week without administration of HY7801, the rest was tested in the same manner as the method of the HY7801 group.

Lastly, the untreated group was tested in the same manner as the method of the HY7801 group except that the saline solution was not orally administered only for one week after E. coli infection.

The results are shown in FIG.

As can be seen in Figure 2, as in the E. coli group, urinary tract infection E. coli when the infection in the urinary bladder increased inflammation, but Lactobacillus sp. In the HY7801 group fed HY7801, Lactobacillus sp. It was found that the inflammation in the bladder caused by E. coli was greatly reduced by the inhibitory activity of urinary tract infection of HY7801.

&Lt; Test Example 5 >

Lactobacillus sp. Of HY7801 Candida albicans  Inhibitory activity

(1) Lactobacillus sp. HY7801 was incubated at 37 ° C. for 20 hours using MS liquid medium, and Candida albicans was tested by shaking culture at 25 ° C. for 20 hours using Sabouraud Dextrose liquid medium (Difco, USA). Used for.

(2) Lactobacillus sp of (1). 10 μl of the culture solution of HY7801 was inoculated into MS agar plates and anaerobicly cultured at 37 ° C. for 2 days. Next, 5 ml of Sabouraud dextrose soft agar medium (0.7% agar) inoculated with Candida albicans (1) at the level of 10 ⁶ cfu / ml was layered. Then, after culturing for 24 hours at 37 ℃ was measured the size of the inhibitory ring of Candida albicans ( Candida albicans ) appearing in the MS agar plate medium.

Lactobacillus sp. The inhibitory activity of Candida albicans by HY7801 is expressed in length (mm) minus the diameter of the metal borer from the diameter of the resulting inhibitory ring.

(3) Lactobacillus gasseri HLAB4-14, Lactobacillus gasseri L18, Lactobacillus brevis LB74, Lactobacillus acidophilus LA04, Lactobacillus ( Lactobacillus gasseri ) L141204, Lactobacillus to frost (Lactobacillus gasseri) L307, ruteri Lactobacillus (Lactobacillus reuteri) MBM4-4, ruteri Lactobacillus (Lactobacillus reuteri) LMB8-2, ruteri Lactobacillus (Lactobacillus reuteri) LMB5-5, Lactobacillus bacteria (Lactobacillus) sp. KM21-1, Lactobacillus sp. KM5-5 and Lactobacillus sp. For KY16-11, Lactobacillus sp. Candida albicans inhibitory activity was tested in the same manner as HY7801.

The results are shown in Fig.

3 shows the Lactobacillus gasseri ( Lactobacillus gasseri ) HLAB4-14, Lactobacillus gasseri ( Lactobacillus gasseri ) L18, Lactobacillus sp. HY7801, Lactobacillus brevis LB74, Lactobacillus acidophilus LA04, Lactobacillus gasseri L141204, Lactobacillus to frost (Lactobacillus gasseri) L307, ruteri Lactobacillus (Lactobacillus reuteri) MBM4-4, ruteri Lactobacillus (Lactobacillus reuteri) LMB8-2, ruteri Lactobacillus (Lactobacillus reuteri) LMB5-5, Lactobacillus bacteria (Lactobacillus) sp. KM21-1, Lactobacillus sp. KM5-5 and Lactobacillus sp. KY16-11 is 'HLAB4-14', 'L18', 'HY7801', 'LB74', 'LA04', 'L141204', 'L307', 'MBM4-4', 'LMB8-2' and 'LMB5-' 5 ',' KM21-1 ',' KM5-5 'and' KY16-11 '.

As can be seen in Figure 3, the Lactobacillus sp of the present invention. The inhibitory ring against Candida albicans of HY7801 was 20 mm, indicating the best inhibitory activity against Candida albicans .

<Test Example 6>

Lactobacillus sp. Hydrogen Peroxide Production Activity of HY7801

(1) Lactobacillus sp. In order to determine the hydrogen peroxide generating activity of the antimicrobial material of HY7801 was prepared as M-MSB agar medium as shown in Table 6. Lactobacillus sp. HY7801 was incubated at 37 ° C. for 20 hours using an MS liquid medium, and then inoculated in an MS-TIB agar plate medium and then anaerobicly cultured at 37 ° C. for 2 days. After incubation, the MS-TIB agar plate medium was exposed to air for 30 minutes and the color change of the fungi formed on the MS-TIB agar plate medium was observed. The degree of change of the color of the cracks to blue was visually observed and divided into 3 grades (+ <2, 2 ≤ ++ <4, 4 ≤ +++).

(2) Lactobacillus gasseri HLAB4-14, Lactobacillus gasseri L18, Lactobacillus brevis LB74, Lactobacillus acidophilus LA04, Lactobacillus ( Lactobacillus gasseri ) L141204, Lactobacillus to frost (Lactobacillus gasseri) L307, ruteri Lactobacillus (Lactobacillus reuteri) MBM4-4, ruteri Lactobacillus (Lactobacillus reuteri) LMB8-2, ruteri Lactobacillus (Lactobacillus reuteri) LMB5-5, Lactobacillus bacteria (Lactobacillus) sp. KM21-1, Lactobacillus sp. KM5-5 and Lactobacillus sp. Also for KY16-11, (1), Lactobacillus sp. Hydrogen peroxide production activity was tested in the same manner as HY7801.

The results are shown in Table 7.

+ <2, 2 ≤ ++ <4, 4 ≤ +++

As can be seen in Table 7, the Lactobacillus sp. Hydrogen peroxide production ability of HY7801 was the best.

<Test Example 7>

Lactobacillus sp. By mixed culture. Of HY7801 Candida albicans  Inhibitory activity

(1) Lactobacillus sp. HY7801 was incubated at 37 ° C. for 20 hours using MS liquid medium, and Candida albicans was tested by shaking culture at 25 ° C. for 20 hours using Sabouraud Dextrose liquid medium (Difco, USA). Used for.

(2) Lactobacillus sp of (1). HY7801 and Candida albicans were inoculated into MS liquid medium at the level of 10 ⁷ cfu / ml, respectively. And shaking culture for 20 hours at 37 ℃ 50 rpm and then measured the number of bacteria of Candida albicans ( Candida albicans ). The bacterial count of Candida albicans was determined by diluting the sample with diluent, and then incubated at 25 ° C. for 2 days after plating on potato dextrose agar plate medium (Difco, USA). After incubation was completed, the colonies formed on the agar plates were counted.

Meanwhile, only Candida albicans was inoculated in MLS liquid medium at the level of 10 ⁷ cfu / ml, shaken and cultured at 37 ° C. at 50 rpm for 20 hours, and then the number of Candida albicans bacteria was measured. To control.

3 Lactobacillus to frost (Lactobacillus gasseri) HLAB4-14, Lactobacillus to frost (Lactobacillus gasseri) L18, Lactobacillus brevis (Lactobacillus brevis), LB74, Lactobacillus ash FIG filler's (Lactobacillus acidophilus) LA04 and Lactobacillus (Lactobacillus ) sp. Also for KY16-11, Lactobacillus sp. Inhibitory activity of Candida albicans by mixed culture was tested in the same manner as HY7801.

The results are shown in Table 8.

As can be seen in Table 8, the Lactobacillus sp. When HY7801 and Candida albicans were mixed and cultured, it was found that the viable cell count of Candida albicans was most suppressed.

<Test Example 8>

Lactobacillus sp. Determination of Adhesion Activity of Vaginal Epithelial Cell A431 by HY7801

Lactobacillus sp. Adhesion activity against A431 cells, the vaginal epithelial cells of HY7801, was tested.

(1) Vaginal epithelial cells A431 was incubated in a 24 well plate with 500 μl per well with medium. DMEM medium (Gifco, USA) with 10% FBS and antibiotics was used as a medium, and cultured at a monolayer of 10 ⁵ cells / well.

Lactobacillus sp. HY7801 was used for the test by incubating for 20 hours at 37 ℃ using MS liquid medium.

(2) Lactobacillus sp of (1). HY7801 was inoculated into wells in which vaginal epithelial cells A431 were cultured at 10 ⁷ cfu / well and incubated at 37 ° C. for 1 hour. After incubation, washed three times with 500 μl / well of PBS and did not adhere to Lactobacillus sp. HY7801 was removed. And 500% of 0.1% triton X-100 was added and reacted for 10 minutes with Lactobacillus sp. A431 cells with HY7801 attached were detached. Lactobacillus sp. In 0.1% triton X-100 solution. Lactobacillus sp. Attached to A431 cells by measuring the number of bacteria of HY7801. It was set as the number of bacteria of HY7801. Lactobacillus sp. The number of bacteria of HY7801 was diluted by diluting the sample, and then inoculated in MLS agar medium and incubated at 37 ° C. for 2 days to count the fungi formed.

3 Lactobacillus to frost (Lactobacillus gasseri) HLAB4-14, Lactobacillus to frost (Lactobacillus gasseri) L18, Lactobacillus brevis (Lactobacillus brevis), LB74, Lactobacillus ash FIG filler's (Lactobacillus acidophilus) LA04 and Lactobacillus (Lactobacillus ) sp. Also for KY16-11, Lactobacillus sp. Adhesion activity to vaginal epithelial cell A431 was measured in the same manner as HY7801.

The results are shown in Table 9.

As can be seen in Table 9, Lactobacillus sp. HY7801 has the best adhesion to vaginal epithelial cells, which has the highest probability of vaginal fixation and survival.

1 is Lactobacillus sp. It is a graph showing the result of measuring the inhibitory effect of urea infection bacteria E. coli ATCC25922 of HY7801.

Figure 2 is a Lactobacillus sp in urinary tract infections in experimental animals of E. coli. It is a graph showing the result of having measured the inhibitory effect of bladder inflammation caused by HY7801 feeding.

3 is Lactobacillus sp. It is a graph showing the result of measuring the inhibitory effect of Candida albicans tm causing Candida vaginitis of HY7801.

Claims (23)

delete delete delete delete delete delete delete Lactobacillus sp., Which has activity to inhibit urinary tract infection. Pharmaceutical composition for treating and preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Escherichia coli (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus (Staphylococcus aureus), Acinetobacter half Mani Lactobacillus bacteria (Lactobacillus inhibit any one or more of (Acinetobacter banmanii), or has an activity to inhibit the adhesion to the bladder epithelial cells of Escherichia coli (E. coli) ) sp. Pharmaceutical composition for treating and preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has the activity of inhibiting candida vaginitis. Candida vaginitis treatment and prevention pharmaceutical composition containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Candida albicans ( Candida albicans ) has the activity of inhibiting or excellent vaginal epithelial cell adhesion activity Lactobacillus ( Lactobacillus ) sp. Candida vaginitis treatment and prevention pharmaceutical composition containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has activity to inhibit urinary tract infection. Fermented milk for preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Escherichia coli (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus (Staphylococcus aureus), Acinetobacter half Mani Lactobacillus bacteria (Lactobacillus inhibit any one or more of (Acinetobacter banmanii), or has an activity to inhibit the adhesion to the bladder epithelial cells of Escherichia coli (E. coli) ) sp. Fermented milk for preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has the activity of inhibiting candida vaginitis. Fermented milk for the prevention of Candida vaginitis containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Candida albicans ( Candida albicans ) has the activity of inhibiting or excellent vaginal epithelial cell adhesion activity Lactobacillus ( Lactobacillus ) sp. Fermented milk for the prevention of Candida vaginitis containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has activity to inhibit urinary tract infection. Functional drink for preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Escherichia coli (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus (Staphylococcus aureus), Acinetobacter half Mani Lactobacillus bacteria (Lactobacillus inhibit any one or more of (Acinetobacter banmanii), or has an activity to inhibit the adhesion to the bladder epithelial cells of Escherichia coli (E. coli) ) sp. Functional drink for preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has the activity of inhibiting candida vaginitis. Functional drink for the prevention of Candida vaginitis containing HY7801 (Accession Number: KCTC 11315BP) as an active ingredient. Candida albicans ( Candida albicans ) has the activity of inhibiting or excellent vaginal epithelial cell adhesion activity Lactobacillus ( Lactobacillus ) sp. Functional drink for the prevention of Candida vaginitis containing HY7801 (Accession Number: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has activity to inhibit urinary tract infection. Functional food for preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Escherichia coli (E. coli), Proteus vulgaris (Proteus vulgaris), Proteus mirabilis , Klebsiella oxytoca , Klebsiella pneumonia , Morganella morganii , Citrobacter freundii , Enterococcus fecalis , Enterobacter cloaca , Pseudomonas aeruginosa , Streptococcus aureus (Staphylococcus aureus), Acinetobacter half Mani Lactobacillus bacteria (Lactobacillus inhibit any one or more of (Acinetobacter banmanii), or has an activity to inhibit the adhesion to the bladder epithelial cells of Escherichia coli (E. coli) ) sp. Functional food for preventing urinary tract infections containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Lactobacillus sp., Which has the activity of inhibiting candida vaginitis. Candida vaginitis preventive health functional food containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient. Candida albicans ( Candida albicans ) has the activity of inhibiting or excellent vaginal epithelial cell adhesion activity Lactobacillus ( Lactobacillus ) sp. Candida vaginitis preventive health functional food containing HY7801 (Accession No .: KCTC 11315BP) as an active ingredient.

Images